| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Canadian Journal of Anesthesia, Vol 38, 75-89, Copyright © 1991 by Canadian Anesthesiologists' Society
ARTICLES |
PG Durand, JJ Lehot and P Foex
Department of Anaesthesia and Intensive Care, Hopital Cardio-vasculaire et Pneumologique, Lyon, France.
Verapamil was the first calcium-channel blocker (CCB). It has been used since 1962 in Europe then in Japan for its antiarrhythmic and coronary vasodilator effects. The CCB have become prominent cardiovascular drugs during the last 15 years. Many experimental and clinical studies have defined their mechanism of action, the effects of new drugs in this therapeutic class, and their indications and interactions with other drugs. Due to the large number of patients treated with CCB it is important for the anaesthetist to know the general and specific problems involved during the perioperative period, the interactions with anaesthetics and the practical use of these drugs.
This article has been cited by other articles:
![]() |
A. Larsen and J. D. Tobias Nicardipine for the Treatment of Hypertension Following Cardiac Transplantation in a 14-Year-Old Boy Clinical Pediatrics, May 1, 1994; 33(5): 309 - 311. [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |